Agenda for iBEAt/BEAt-DKD participant event on Wednesday 30th of August

Please note that times are in UK / BST times so will need to be amended for your centre. (Start time in Sweden and Italy: 10am; Start time in Finland: 11am).

9 am	Welcome
	Kim Gooding, University of Exeter, UK
9.05 am	What is the BEAt-DKD consortium? Why is it interested in diabetic kidney disease?
	Maria Gomez, Lund University, Sweden
	Academic lead for BEAt-DKD consortium
9.25	What is the iBEAT / BEAT-DKD study that you are participating in trying to do? How does it work across all the different centres?
	Kim Gooding, University of Exeter, UK
	Co-Lead for the iBEAT/BEAT-DKD study
9.45	Why are you looking at the amount of fat and where it is in my MRI images?
	Paul Hockings, Senior Imaging Director, Antaros Medical, Sweden
	Lead Centre for performing MRI fat measurements
9.55	Why do I need to be in the MRI scanner for so long? What information are you getting from the MRI images of my kidneys?
	Soe Kywe Kywe. University of Sheffield Lead MRI image analysis centre
10.15	Break
10.30	Why are you collecting so much of my blood and urine? What happens to my blood and urine samples?
	Maria Gomez
	Academic lead for BEAt-DKD consortium and the lead for the Central iBEAT Laboratory
10.45	Why are participants in Bari also having a kidney biopsy? Why is this important?
	Loreto Gesualdo, University of Bari Aldo Moro, Italy
	Consultant Physician and Lead for iBEAT Kidney Biopsy Study
10.55	What is the microvascular study in Exeter? Why are we interested in the smallest blood vessels?
	Angela Shore, University of Exeter, UK
	Lead for microvascular study
11.05	Why are big pharmaceutical / drug companies interested in being involved with BEAt-DKD consortium and other similar consortium.
	Anil Karihaloo
	Sr Principal Research Scientist, Novo Nordisk, USA
11.10 -	

	Future plans
	Closing the session – Kim Gooding